Memphasys Ltd (AU:MEM) has released an update.
Memphasys Ltd is on the brink of completing its clinical trial for the Felix™ System, having reached 90% completion with plans to finish by year’s end. The company is strategically shifting focus to obtain CE mark registration in Europe, aiming for a quicker market entry compared to the Australian approval process. This approach positions Memphasys to capitalize on larger market opportunities and potentially accelerate partnerships and investments.
For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.
